DRG Market Assessment reports

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…

Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Despite the need…

Historically, metformin and the sulfonylureas were the most-prescribed drugs for type 2 diabetes. These agents dominated the early lines of therapy until disease progression required insulin…

Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…

Diabetic macular edema (DME) occurs as a consequence of diabetes. It typically develops in the advanced stage of diabetic retinopathy and is characterized by leaking fluid from abnormal blood…

MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typical treatments for this…

For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine…

Parkinson’s disease (PD) treatment is complex. The disease is heterogeneous, requiring individualized treatment and frequent adjustments to achieve symptom control. New therapies that address PD…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines. Migraine prophylaxis, though underused, is a core treatment approach to reduce migraine frequency,…

Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…

Market Outlook Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-…

MARKET OUTLOOK The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (…